Volitionrx (VNRX) EBIT (2012 - 2025)

Volitionrx has reported EBIT for 10 years, with the latest figure at -$4.8 million in Q4 2025.

• For the quarter ending Q4 2025, EBIT rose 16.66% year-over-year to -$4.8 million; the trailing twelve-month figure through Dec 2025 stood at -$21.7 million (up 19.56% YoY), and the FY2025 full-year result was -$21.7 million, up 19.56% from the prior year.
• EBIT for Q4 2025 stood at -$4.8 million, up from -$5.1 million in the prior quarter.
• The five-year high for EBIT was -$4.8 million in Q4 2025, with the low at -$9.5 million in Q2 2023.
• Historically, EBIT has averaged -$7.2 million across 5 years, with a median of -$7.6 million in 2021.
• Annual changes were most pronounced in 2021 — EBIT plunged 67.89% — and 2025, when it soared 34.14%.
• Volitionrx's EBIT stood at -$8.8 million in 2021, then gained by 8.81% to -$8.0 million in 2022, then fell by 9.11% to -$8.7 million in 2023, then jumped by 33.86% to -$5.8 million in 2024, then increased by 16.66% to -$4.8 million in 2025.
• The last three EBIT figures came in at -$4.8 million (Q4 2025), -$5.1 million (Q3 2025), and -$6.3 million (Q2 2025), per Business Quant data.